Company Description
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers.
In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services.
It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022.
Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
| Country | United States |
| Founded | 1944 |
| Industry | Healthcare Plans |
| Sector | Healthcare |
| CEO | Gail Boudreaux |
Contact Details
Address: 220 Virginia Avenue Indianapolis, Indiana 46204 United States | |
| Phone | 833 401 1577 |
| Website | elevancehealth.com |
Stock Details
| Ticker Symbol | ELV |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001156039 |
| CUSIP Number | 036752103 |
| ISIN Number | US0367521038 |
| Employer ID | 35-2145715 |
| SIC Code | 6324 |
Key Executives
| Name | Position |
|---|---|
| Gail Koziara Boudreaux | President, Chief Executive Officer and Director |
| Mark Bradley Kaye | Executive Vice President and Chief Financial Officer |
| Peter David Haytaian Esq. | Executive Vice President and President of Carelon and CarelonRx |
| Charles Morgan Kendrick Jr. | Executive Vice President and President of Commercial Health Benefits |
| Felicia Farr Norwood | Executive Vice President and President of Government Health Benefits |
| Scott Wayne Anglin | SVice President, Treasurer and Chief Investment Officer |
| Ronald William Penczek | Senior Vice President, Controller and Chief Accounting Officer |
| Blair Williams Todt | Executive Vice President and Chief Legal and Administrative Officer |
| Nathan Allen Rich | Vice President of Investor Relations |
| Julie Goon | Senior Vice President of Public Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 20, 2025 | 10-K | Annual Report |
| Jan 23, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |